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Abstract
Cell culture-based transdominant genetic techniques provide new methods for discovering peptide/RNA modulators of cellular pathways.
We applied this technology to isolate a peptide inhibitor of human rhinovirus. A green fluorescent protein (GFP)-scaffolded library of cDNA
fragments was expressed in HeLa cells from a retroviral vector and screened for inhibitors of rhinovirus-mediated cell killing. A DNA clone,
I421, increased cell survival in an HRV14 challenge assay from less than 0.5% to greater than 60%. It encodes a 53-amino-acid C-terminal
extension of the GFP scaffold. Particular subclones of Hela cells expressing I421 (exemplified by I421dp3) show a delay in virus production
and a 50-fold decrease in viral RNA levels at 6–8 h postinfection. HRV2, HRV14, and HRV16 show a dramatic decrease in plaque-forming
ability on I421dp3 while Coxsackievirus B3 showed a small reduction. Levels of ICAM-1, the receptor for the main rhinovirus serotype,
are not altered in I421dp3.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
There is a pressing need for new antiviral drugs for a
variety of viruses, including HIV, HBV, and HCV (Boyer
and Marcellin, 2000; De Clercq, 2001; Richman, 2001;
Shaw and Locarnini, 2000; Torresi and Locarnini, 2000).
Historically, two general methods have been used to iden-
tify lead compounds with antiviral activity. Whole cell
screens, in which compounds are assayed for inhibition of
virus-mediated cell killing, have led to the identification of
a variety of drugs (e.g., enviroxime (DeLong and Reed,
1980) and pleconaril for human rhinovirus and VP32947
(Baginski et al., 2000) for bovine viral diarrhea virus).
Alternatively, knowledge of viral protein structure and
function has enabled screens for compounds that inhibit
specific enzymatic activities (e.g., viral proteases (Patick
and Potts, 1998)) essential for replication. This latter strat-
egy has also been aided by rational design methods based on
the crystal structures of viral proteins (e.g., the influenza
neuraminidase (Lew et al., 2000) and the rhinovirus pro-
tease (Patick et al., 1999) and capsid (Badger et al., 1988)).
A much smaller number of antiviral therapies involve mod-
ulating host functions or proteins, for example, interferon
treatment for HCV (Taylor, 2000). Despite an increase in
our understanding of the viral–host interactions necessary
for the replication of viruses, the number of obvious anti-
viral targets has remained limited.
Recent developments in the ability to perform functional
screens for transdominant factors may provide another strat-
egy for the identification of novel antiviral drug targets and
ultimately lead to compounds with new specificities (Kamb
and Teng, 2000; Roninson et al., 1995). These techniques
combine aspects of expression cloning with the cycling
methods of SELEX or phage display to enrich, from com-
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plex DNA libraries, those rare molecules that encode pep-
tides or RNAs that confer desired phenotypes; we have
termed these transdominant agents “perturbagens”; i.e., fac-
tors that perturb a cellular process and thereby induce a
selective phenotype.
To date, several successful high complexity, en masse
transdominant genetic selections have been executed. From
a screen for genetic suppressor elements (GSEs) that confer
resistance to the anticancer drug etoposide on mouse cells,
Gudkov et al., (1994) reported the identification of three
factors including an anti-sense kinesin clone. In the budding
yeast, Saccharomyces cerevisiae, three groups indepen-
dently screened for suppressors of the pheromone response
pathway and identified numerous peptide inhibitors of pher-
omone-induced cell cycle arrest (Caponigro et al., 1998;
Geyer and Brent, 2000; Norman et al., 1999). Blum et al.,
(2000) isolated two peptide aptamer inhibitors of the thy-
midylate synthase enzyme in Escherichia coli and five
aptamers with bacteriocidal activity. Xu et al. (2001) re-
ported the isolation of peptides that confer resistance to
taxol-induced cytotoxicity, while Beger et al. (2001) iden-
tified a ribozyme-based regulator of BRCA1 expression.
There are also several reports of screens using lower com-
plexity, targeted libraries. Of particular relevance to the
present work, Holzmayer and colleagues employed a library
derived from random fragments of the HIV genome to
identify GSEs (both sense and antisense fragments) with
antiviral activity (Dunn et al., 1999).
In this report, we describe the optimization of a rhino-
virus-mediated human cell cytopathic assay suitable for
performing a transdominant screen for antiviral agents. Ex-
ecution of an en masse selection with a high-complexity
cDNA library resulted in the isolation of a perturbagen that
inhibits the virus’ life cycle. Initial characterization of per-
turbagen-carrying cells infected with HRV suggests that it
acts at or before the step of RNA replication. We discuss the
utility of perturbagens for identifying antiviral drug targets.
Results
Establishment of a rhinovirus bioassay
Several issues are important for the successful execution
of an antiviral perturbagen screen. First, the host cell should
be amenable to retroviral transduction and allow high levels
of expression of the introduced library. Using flow cytom-
etry and retroviral vectors bearing a constitutive CMV-
promoter-driven GFP reporter, we ascertained that the H1
subline of HeLa cells, commonly used for growing HRV, is
efficiently transduced by VSV-G pseudotyped retroviruses
and that the transduced constructs are strongly expressed
(data not shown). Second, H1-HeLa cells are efficiently
infected and killed by the HRV14 and the virus can be
grown to high titer thus allowing the infection of hundreds
of millions of cells at high m.o.i. Third, selection of cells
displaying the phenotype of interest is straightforward.
Since HRV infection of HeLa cells results in host cell death,
isolation of antiviral peptides involves a simple selection for
cells resistant to the viral assault. Finally, for maximal
enrichment of a perturbagen during each cycle of the selec-
tion, the bioassay should be tailored to have a low back-
ground (i.e., non-perturbagen-carrying cells do not survive
the infection) but concurrently optimized for sensitivity
(cells carrying active perturbagens frequently survive the
infection). Reinfection by progeny virus at a high, uncon-
trolled m.o.i., will lower the recovery of weak perturba-
gens. To suppress this effect we employed two independent
strategies specific to rhinovirus: an HRV14 neutralizing
antibody (mAb17) and heat shock. Specifically, mAb17 was
added 4 h after the HRV infection while the shift in tem-
perature from 33 to 39°C occurred about 24 h postinfection
(see Materials and Methods). With both blocks in place, we
titrated the HRV m.o.i. to reproducibly achieve survival
frequencies between 1/100 and 1/1500 in our assay at 48 h
postinfection.
Selection for HRV resistance
Using the optimized bioassay, we executed a selection
for transdominant agents that conferred rhinovirus resis-
tance (diagrammed in Fig. 1). A human placental random-
primed cDNA library of 12 106 complexity was packaged
into retrovirus and transduced into HeLa cells. The cDNAs
were cloned at the 3 end of a nonfluorescent GFP variant
(Methods and Fig. 1) such that the cloned fragments were
expressed as C-terminal extensions of GFP. These trans-
duced cells were infected with HRV14 at an m.o.i. of 10 and
then treated with anti-HRV antibodies and heat shock. Cells
that survived the HRV14 infection were used as a source for
genomic DNA from which to PCR amplify the retroviral
cDNA inserts. To enrich for active perturbagens, the recov-
ered cDNA fragments were recloned into the retroviral
vector, packaged into retrovirus particles using 293gp cells,
and transduced into naı¨ve HeLa cells for another round of
selection. This cycling process was iterated until significant
HRV14 resistance was conferred by the sublibrary relative
to the vector (352.1) control.
Starting with the same initial cDNA library transduced
into HeLa cells, two independent HRV14 selections (“A”
and “B”) were performed in parallel. The difference be-
tween the two screens was that the B series involved a more
stringent initial round (less than 1/60,000 cells surviving
two successive infections with HRV14 compared to 1/1300
survivors for the A series, see Fig. 2 legend for details). The
A and B selections followed standard conditions after the
first round (see Materials and Methods). Under these con-
ditions survival of the cells transduced by the vector control
(352.1) ranged from 0.1 to 1.0%, occasionally getting as
high as 1.5%. As shown in Fig. 2, the fraction of HeLa cells
surviving HRV14 infection changes dramatically over the
course of four rounds of selection. Initially, the percentage
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of surviving cells observed in library-containing popula-
tions mirrored the number observed in the control (Fig. 2,
Vector) and was less than 0.1%. By the end of four rounds
of cycling, the fraction of HRV14 resistant cells in the
sublibrary populations was 1.1% in group A and 6.6% in
group B, respectively; this corresponds to a 14- to 426-fold
increase in signal over the vector control background, de-
pending upon the sublibrary measured. More important than
the fold increase over background (which suffers from the
variability in background described above), we observed
close to the same absolute signal in independent transduc-
tions of a given sublibrary (data not shown).
Throughout the selection process, we investigated the
representation of clones within a given sublibrary by se-
quence analyses. Following each cycle of selection, ran-
domly chosen clones from each sublibrary were isolated and
the cDNA fragments were sequenced. Altogether, several
hundred clones isolated from the sublibraries prepared from
cycles one through three were analyzed and grouped based
on sequence identities. Clones that enriched through the
series of selections, i.e., those that were present at higher
frequencies in the later sublibraries relative to the earlier
ones, were repackaged in 293gp cells and tested individu-
ally for their ability to block HRV14-mediated cytotoxicity
in the HeLa bioassay.
Fig. 1. Schematic of the perturbagen selection. See text for details. Abbreviations: LTR, long terminal repeats of the retroviral vector; Neo, neomycin
resistance gene; CMV, cytomegalovirus immediate early promoter; dGFP, dead (nonfluorescent) variant of green fluorescent protein.
Fig. 2. Fraction of cells surviving infection in each cycle of the perturbagen
selection. The percentage of survivors for a given transduced cell popula-
tion is calculated as the number of cells recovered from an infected plate
divided by the number of cells recovered from an uninfected plate treated
in parallel (see Materials and Methods). Vector refers to cells transduced
with the parent vector (pVT352.1) in parallel with the libraries. Twenty
million cells were transduced with the parental library and grown out for 4
days at 33°C. One hundred million cells were infected with HRV14,
mAb17 was added at 4 h, and the cells were washed at 24 h. Because cell
killing was less than expected, the experiment was split in two. Half of the
cells (group A) were allowed to incubate for a period of 5 days before
being harvested. Group B cells were washed at 24 h postinfection, rein-
fected a second time at 48 h, and then harvested at 5 days. The percentage
survival of this round is shown as Cycle 0. Five to ten million cells were
transduced with sublibraries from the two groups in subsequent rounds of
cycling and the HRV14 infection and blocking steps were identical (see
Materials and methods).
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Characterization of an anti-HRV perturbagen
One particular sequence group, represented by the I421
clone, was found in multiple sublibraries (those prepared
from cycles two and three of both series A and B) and was
present 28 times out of the 623 clones sequenced. When
I421 was reintroduced into HeLa cells and subsequently
challenged with HRV14, a substantial fraction of the I421-
containing population was resistant to viral-induced cell
death (Fig. 3A, I421 compared to Vector). In numerous
independent experiments, 20 to 60% of the I421-containing
population was virus resistant compared to 0.1 to 0.8%
observed in the vector control populations (representative
data in Fig. 3A).
Sequence analysis showed that the I421 perturbagen con-
sisted of a 312-base-pair cDNA fragment of repetitive DNA
that coded for a 53-amino-acid peptide fused to the dGFP
scaffold (Fig. 4Fig. 4). Based on nucleotide sequence com-
parisons against Genbank (BLASTN algorithm, (Altschul et
al., 1997)), it appears that I421 is derived from a single copy
sequence on chromosome 20 in the human genome (nucle-
otides 23,490 to 23,800 of Genbank Accession No.
AL050326) with no significant similarity to entries in the
database of expressed sequence tags (dbEST). The peptide
Fig. 3. Penetrance and expression levels of the I421 perturbagen. HeLa cells were transduced and neomycin selected with the retroviral vector (pVT352.1),
I421, and a I421-OF construct in which the I421 coding sequence is out-of-frame with the dGFP sequence because of a 4-bp insertion (see Fig. 4). (A) Assay
of the HRV14 resistance of the cells was performed in a T175 flask as described for cycling the library. Percentage survivor is defined as in Fig. 2. (B) Western
blot of total protein from these cells probed with an anti-GFP antibody. Untransduced HeLa cells are negative for GFP expression. The coding sequence of
the I421-OF GFP fusion protein terminates 5 aa past the SfiB site while that of the vector control, 352.1, extends 16 aa past the SfiB site into the stuffer
fragment.
Fig. 4. I421 DNA and protein sequence. The I421 perturbagen consists of 323-base-pair cDNA fragment fused downstream of a dead GFP scaffold. Shown
are the DNA sequences at the 3 end of GFP together with the Sfi I linker (lowercase) followed by the inserted I421 fragment (uppercase). The Sfi I junction
of the GFP–I421 fusion is underlined and the translation stop codon is indicated in bold. The encoded amino acid sequence is indicated above the DNA
sequence in italics. An open-ended box encloses the C-terminal residues of canonical GFP (all but the last amino acid of wild-type GFP are present). The
out-of-frame variant of I421 shown in Fig. 3 was constructed by filling in the BsrG I site immediately 5 of the Sfi I site depicted to add the four bases GTAC.
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encoded by I421 shows a strong bias in amino acid com-
position; the first half is highly negatively charged (11 Asp
and 1 Glu residues out of 27) while the second half is
extremely hydrophobic (11 Met, 7 Val, 1 Ile, and 2 Leu out
of 26).
To ascertain if the mode of action of the I421 was at the
protein or the RNA level, we made and tested an out-of-
frame version of the perturbagen that should express essen-
tially the same RNA sequence but an alternate peptide fused
to the dGFP scaffold (see Fig. 4 legend). In contrast to the
original I421 perturbagen, HeLa cells transduced with the
out-of-frame construct exhibited no antiviral activity (Fig.
3A, I421-OF). An anti-GFP immunoblot was performed to
show that both the in- and out-of-frame constructs of I421,
and by inference their mRNAs, were expressed at equiva-
lent levels, indicating that the lack of an effect in the
bioassay by the out-of-frame construct was not due to lower
expression levels (Fig. 3B). Taken together, the data support
the notion that I421 acts as a peptide rather than as an RNA
molecule.
Single-step growth curves
To begin investigating the I421 mechanism of action,
single-step virus growth curves were performed on HeLa
cells transduced with either the I421 perturbagen or the
control vector. Viral titers produced by the different cells
during this time course study were quantified by TCID50
assay. Fig. 5 shows that the burst size from a population of
I421-containing HeLa cells infected with HRV14 appeared
to be identical to that of comparably infected control cells at
all times after infection. This result is consistent with het-
erogeneity within the I421-transduced population (e.g., due
to different cell-to-cell expression levels; see Discussion).
If, for example, 50% of the cells survived rhinovirus infec-
tion, then the remaining half that succumbed may still pro-
duce a normal burst of virus; a two to three fold reduction
in viral titer would be less than the measurement error of the
TCID50 assay and thus would not be detectable.
Phenotypes of cloned cell lines expressing I421
To eliminate the source of heterogeneity and to investi-
gate whether heritable differences in virus resistance and/or
virus production existed within the I421-containing HeLa
population, individual cell clones were isolated, expanded
under neomycin selection, and examined for changes in the
HRV14 burst size. Analysis of two of the lines I421dp2 and
I421dp3 (dp for delayed production) showed that the yields
of viral progeny at the 6- and 8-h time points were approx-
imately 50-fold lower than those of parent HeLa cells trans-
duced with either I421 or vector control (Fig. 5), suggesting
that one or more stages of virus replication was inhibited
and/or delayed in these lines. Of interest, 10 h postinfection,
the level of virus produced in the I421dp clones rose to
within roughly five fold of control cells, implying that I421
confers a delay and a partial block on virus production.
We next asked whether the delay in viral maturation and
reduction in viral burst size in the I421dp lines inhibited
plaque formation by HRV14 on these cells. Lawns of
I421dp3 or vector transduced cells were infected with in-
creasing amounts of HRV14 and the resulting plaques ex-
amined 3 days later (Fig. 6). The plaques were more nu-
merous on the vector control than on the I421dp3 cells at
every level of virus inoculum. We also tested two other
serotypes of rhinovirus, HRV16 and HRV2, as well as the
related picornavirus, Coxsackievirus B3. As with HRV14,
both HRV16 and HRV2 showed a large decrease in the
ability to form plaques on I421dp3 cells compared to the
vector control. In contrast the Coxsackievirus showed a
modest reduction in plaque-forming ability. These data
demonstrated that I421 dramatically reduces the capacity of
several different rhinovirus serotypes to productively infect
and kill host cells.
To determine the frequency of the dp phenotype among
cells transduced with I421, we characterized nine randomly
selected, neomycin-resistant sublines of I421-transduced
cells for their phenotypes with respect to plaque formation
by HRV14. Four of the lines showed the phenotype de-
scribed for the I421dp3 cells, i.e., no plaque formation. Two
of the lines supported plaque formation with wild-type ef-
ficiency. These lines showed no detectable expression of
GFP (encoded by the scaffold in I421) by Western blot (data
not shown) despite the fact that they were resistant to
neomycin. Finally, cells from three of the sublines were
completely killed in the course of the plaque assay even in
the absence of rhinovirus, suggesting that their viability at
high density was impaired. By contrast 10 of 10 sublines
from cells stably transduced with the 352.1 vector exhibited
normal plaque formation and normal growth in the plaque
assay. These data suggest that the HRV14 plaque inhibition
Fig. 5. Single-step growth curve on different I421 transduced populations.
Pools of cells (106 cells/ml) transduced with the vector (352.1) (), I421
() and selected cell clones (I421dp2(o) and I421dp3(x)) were mixed with
HRV14 (m.o.i. of 10) and incubated for 30 min in DMEM2%. The cells
were washed twice and resuspended in 3-ml aliquots of 0.5106 cells; this
step was defined as t  0. At the indicated times samples were frozen at
80°C and titered. Aliquots of the cell and virus mixture before (t  30
min) and after the incubation (t  5 min) were also titered.
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observed in the I421dp clones is not a rare event nor does
the retroviral vector alone mediate it.
I421 inhibits HRV plus-strand RNA synthesis
Because I421dp3 cells showed a strong HRV14 resis-
tance phenotype in the plaque assay and a kinetic delay in
virus production in the single-step growth curve, these cells
were further studied to determine more precisely the step in
the virus life cycle that was blocked. We used RNA blot
analysis to quantitate the level of viral RNA synthesis in
infected cells (Fig. 7). HRV14 infection of cells transduced
with either 352.1 (Vector) or the perturbagen (I421) led to
a rapid increase in viral positive-strand RNA up to and
including the last time point measured at 16 h postinfection.
Because cells were beginning to float off the plate and to
lyse by 16 h it was difficult to examined later time points in
this assay. As was observed for the viral yield (Fig. 5), there
was no difference in RNA synthesis between the pertur-
bagen and the control pools of transduced cells. In contrast
the I421dp3 subline demonstrated a marked reduction at all
time points (25-fold at 16 h postinfection). This result ex-
plains the low virus yield at the 6- and 8-h time points
observed in the single-step growth curve although it may
Fig. 6. Plaque assay. Two million cells (a pool of 352.1 vector-transduced cells, “V,” or the I421 selected clone “dp3,” as indicated) were plated in 6-cm
dishes in DMEM10% at 33°C. One day later the cells were infected with 25,250, and 2500 pfu of HRV14, HRV16, HRV2, and CoxB3 as indicated in
1.5 ml of DMEM2%. After 1 h, the media was replaced with 4 ml of 1% molten SeaPlaque agarose (FMC) in DMEM2% and the cells were incubated
at 33°C for 3 days. Plaques were visualized by fixing the cells in methanol and staining with 0.2% crystal violet in PBS containing 10% formalin. Although
Coxsackievirus is often propagated at 37°C, in the assay shown here the cells were grown at 33°C because the I421dp3 phenotype has only been characterized
at 33°C.
Fig. 7. HRV14 plus-strand RNA synthesis in I421-transduced cells. One million cells per 6-cm dish were infected with HRV14 at a m.o.i. of 10 for 60 min.
At the time points noted total RNA was harvested and analyzed by blotting and hybridization with a HRV14 positive-strand probe as described under
Materials and Methods. Vector, I421, and I421dp3 refer to the cell populations indicated in Figs. 5 and 6. Arrows mark the position of the 18S and 28S rRNA
bands.
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not explain the rise in titer late in infection (Fig. 5, I421dp2
and I421dp3 at 10–14 h).
I421 does not induce heat shock, depress ICAM1 levels,
or alter cell proliferation rates
Given that growth of HeLa cells at elevated temperatures
confers resistance to HRV, it is conceivable that the pertur-
bagen I421 induces an antiviral state by inducing a consti-
tutive heat shock response. To investigate this possibility,
protein extracts from HeLa cells stably transduced with
I421 or the vector control and grown at different tempera-
tures were probed on a Western blot with antibodies that
recognize the inducible isoform of HSP 70. Fig. 8 shows
that at 33°C the level of HSP70 was the same in both the
vector- and the I421-transduced cells and that both popula-
tions showed the same increase with temperature. These
results suggest that I421 does not induce a constitutive heat
shock response.
Another potential mechanism by which I421 confers
HRV14 resistance is to reduce the levels of the ICAM1
receptor required for viral entry. To examine this possibil-
ity, Hela cells and derivative lines stably transduced with
I421 or the vector control were immunostained with either
labeled anti-ICAM1 monoclonal antibodies or an isotype
control and analyzed by flow cytometry (Fig. 9). All of the
lines expressed similar levels of cell surface ICAM1; spe-
cifically the mean relative fluorescence units (RFU) for the
different lines were as follows: Hela, 454 RFU; vector, 375
RFU; I421dp3, 502 RFU; I421 pool, 427 RFU (data not
shown), compared to the isotype control staining of 7 to 9
RFU for all four lines. This suggests that I421 is not simply
blocking HRV infection by lowering the level of the virus’s
receptor.
Finally, we ascertained that I421 did not affect the growth
rate of HeLa cells by monitoring cell growth over a 7-day time
course (Fig. 10). The doubling times at 33°C calculated from
this data did not differ significantly among the cells tested
Fig. 8. HSP 70 levels in HeLa cells expressing I421. Pools of neomycin selected 352.1 vector-transduced cells (V) or perturbagen-transduced cells (I421)
were grown for 3 days at the indicated temperature before being harvested. Proteins extracts were fractionated on a polyacrylamide gel and then stained with
Coomassie blue or subjected to Western analysis using anti-HSP 70 antibodies. The Coomassie-stained gel serves as a control for equal loading of the protein
lysates.
Fig. 9. Fluorescence histograms of cells stained with ICAM1 antibodies.
Hela (  ) 352.1 vector transduced (—), and I421dp3 ( ) cells were
stained with an isotype control antibody (A) or anti-ICAM1 (B) as de-
scribed under Materials and Methods. Histograms were gated on the peak
80% of cells in the forward scatter vs side scatter bivariate plot to avoid
analyzing cell clumps.
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(Hela, 45 h; vector, 38 h; I421 pool, 42 h; I421dp3, 41 h). This
suggests that I421 is not inhibiting HRV replication by a
nonspecific toxic effect on the host cell.
Discussion
Optimizing a selection for antiviral perturbagens
Certain issues are central to all high-complexity, en
masse genetic selections from libraries (Irvine et al., 1991;
Levitan, 1998; Sandrock et al., 2001a). Based on a few
transdominant selections that have been executed to date,
the frequency of active perturbagens within a complex
(106) expression library is generally low (at most 1/105 to
1/106) (Beger et al., 2001; Caponigro et al., 1998; Geyer and
Brent, 2000; Gudkov et al., 1994; Norman et al., 1999; Xu
et al., 2001). The anti-HIV GSEs isolated by Dunn et al.
(1999) appeared at a much higher frequency (Table 2 of
Dunn et al. (1999) suggests an aggregate frequency of
1/6000). This suppports the notion that the (low-complex-
ity) viral genome is enriched for potential dominant nega-
tive factors. Further work will determine whether screens
using high-complexity libraries (cDNA or peptide) identify
targets missed by the viral genome approach.
As with SELEX or phage display screens, the transdomi-
nant genetic screen that we have performed to isolate anti-
HRV perturbagens required several rounds of selection (cy-
cling) to achieve sufficient enrichment to identify individual
molecules conferring the desired activity. To a first approx-
imation, enrichment in a given round of selection is gov-
erned by the following equation:
Enrichment
penetrance of perturbagen
background of assay .
For example, in the HeLa cell/HRV14 resistance assay of
Fig. 3A, I421 displays a signal of about 25% when the
background of the assay was 0.3%; thus, the penetrance
of I421 under these conditions is roughly 25% (signal
minus background). Thus, the approximate enrichment
per cycle of selection is 25%/0.3%, or 83-fold. In prin-
ciple, the lower the background in the selection, the
greater the enrichment. However, a very stringent selec-
tion in which few nontransduced cells survive may not
result in optimal enrichment because the perturbagen-
expressing cells may not survive as well due to the harsh
conditions. Conversely, a weak selection that allows
100% survival of perturbagen-carrying cells may have
high backgrounds of nonspecific survivors; this lowers
the effective enrichment.
With cytopathic viruses it is not difficult to achieve a low
background of surviving cells; infecting host cells at an
MOI as low as 7 should, in theory, leave less than one cell
in 1000 uninfected by the initial inoculum. The difficulty
comes in harvesting the survivors before they become over-
whelmed by the extremely high MOI due to progeny virus.
Fig. 10. Growth rate of HeLa cells expressing I421. Fifty thousand cells (Hela, ; 352.1, ; I421, x; I421dp3, Œ) per T25 flasks were plated in 4 ml of
DMEM10% at 33°C. On the days indicated cells were trypsinized and counted using a hemocytometer. The data shown are the average (106) of three
plates per cell line per time point.
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This is especially true if an uninfected cell cannot be sep-
arated from its productively infected neighbors before they
release the progeny virus.
We have utilized two methods to minimize secondary
HRV infections during the course of the selection: an
HRV14 neutralizing antibody and heat-shock-induced rhi-
novirus resistance. The monoclonal antibody, mAb17-IA,
which binds to the NIm-IA site of the HRV14 capsid, is
highly effective in binding rhinovirus and preventing virus
infection (Colonno et al., 1989; Sherry et al., 1986). The
antibody is not toxic to uninfected HeLa cells, even at the
highest concentrations tested (data not shown); thus we
were able to use an excess of mAb to inhibit secondary
infection. As a second independent block, we took advan-
tage of the fact that rhinovirus replication is extremely
sensitive to heat shock (Conti et al., 1999; Killington et al.,
1977; Stott and Heath, 1970). HRV abortively infects cells
grown at 39°C. The high-temperature block is associated
with enhanced degradation of HRV RNA and it appears to
reflect induction of the heat shock response per se rather
than a temperature-sensitive factor in viral replication
(Conti et al., 1999). We have observed that growth at 39°C
also suppresses the cytotoxicity of HRV14 infection (data
not shown). Thus, applying a temperature block after the
initial round of infection, but before substantial reinfection
has occurred, enhanced the survival of cells showing viral
resistance. When applying a perturbagen screen to other
viruses for which a temperature block is not available, it
may be sufficient to use only one blocking step to minimize
secondary infections. Alternatively, a combination of anti-
bodies that recognize independent epitopes on the virus or
the use of existing antiviral drugs against the virus should
control reinfection.
Several different scaffolds, such as E. coli thioredoxin
(Blum et al., 2000; Colas et al., 1996), A. victoria GFP
(Caponigro et al., 1998), and staphylococcal nuclease (Nor-
man et al., 1999), have been employed for the presentation
of a library of transdominant peptides. In the case of enzyme
scaffolds like thioredoxin and nuclease, the catalytic activ-
ities were inactivated by mutations to render the protein
inert. The accepted primary reason for utilizing a scaffold is
to increase protein stability; as a fusion to a stable protein,
high levels of expression of the transdominant factor may be
achieved within a cell. Another advantage offered by the
scaffold is the convenience of a tag or readout for detection
and purification purposes. Antibodies are readily available
as probes for these well-characterized scaffolds. Two basic
methods are used to present the transdominant factor on the
scaffold: as a conformationally unconstrained peptide on the
amino- or carboxy-terminal end of the protein or as a con-
strained peptide in an internal loop. These two alternatives
have, in theory, different advantages (Kamb and Caponigro,
2001); both types of scaffolded-peptide libraries have
yielded active perturbagens (Caponigro et al., 1998).
The I421 perturbagen
Although the I421 sequence was isolated from a cDNA
library, it encodes a peptide that may not be derived from a
native protein. Rather, it is a serendipitous translation prod-
uct of a genomic contaminant or cDNA. The repetitive
nature of its sequence yields a highly charged peptide seg-
ment followed by an extremely hydrophobic segment (Fig.
4). The extent to which either of these domains is necessary
or sufficient for antiviral activity will require further study.
Picornavirus RNA replication occurs in membrane com-
plexes and infection promotes extensive reorganization and
proliferation of cellular membranes (Egger et al., 2000).
Conceivably, the hydrophobic C-terminus of I421 allows it
to interfere with some aspect of this process.
The penetrance of I421 in the HeLa/HRV14 resistance
bioassay is incomplete; generally 20–70% of the host cells
survive the viral assault. Accumulated evidence suggests
that one major reason for this partial penetrance is the
variability in expression level of I421 achieved within a
given HeLa cell. Consistent with this notion is the fact that
two of the nine I421 clonal lines tested that exhibited reg-
ular HRV14 plaques, similar to naı¨ve HeLa cells, did not
have detectable levels of I421 by immunoblot. Using flow
cytometry and a fluorescent enhanced GFP reporter ex-
pressed from our standard retroviral vector, we have found
that a population of HeLa cells transduced at a single MOI
displays a broad range of GFP expression ranging over 2
logs of fluorescence (data not shown). This cell-to-cell vari-
ability in expression levels is not specific to the HeLa cell
line as it has also been observed in all other cells lines
examined (Sandrock et al., 2001b). Mechanisms that may
account for the heterogeneous expression include position
effects of the retroviral integration site within a host cell’s
genome or mutation/methylation of the retroviral vector.
We estimate the CMV promoter and GFP-scaffolded per-
turbagen used in the present work generally allow single-
copy expression within mammalian cells in the 1 M range
(Sandrock et al., 2001b). By comparison the activity of
small-molecule antirhinovirus compounds, such as ple-
conaril (mean IC50 of 0.03 M (Pevear et al., 1999)) or
AG7088 (mean IC50 of 0.023 M (Patick et al., 1999)),
appears to be much stronger. However there are at least two
differences between these compounds and the perturbagen
described here. First, I421 is a “first generation” pertur-
bagen that has not been evolved into a more active mole-
cule. Second, small molecule inhibitors are usually added to
the cell culture media and are thus present in a large reser-
voir outside of the cell. This contrasts with the situation for
a perturbagen, in which there is no reservoir for the active
molecule other than what is translated in the cell. It is
therefore plausible that elevated concentrations of an opti-
mized I421 derivative, or a small molecule which mimics its
activity, could cause complete HRV inhibition.
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Mechanism of action of I421
An antiviral perturbagen is a RNA, peptide, or protein
fragment which, when expressed in cells, inhibits a step in
virus replication. In principle a useful perturbagen could
inhibit any step up to and including maturation of the virion.
Because it is technically more difficult to devise screens that
select for inhibition of late steps in the virus life cycle, we
have focused in the present work on inhibitors that prevent
virus-mediated cell death. The Northern blot revealed that
HRV14 RNA replication is severely inhibited in I421dp
subclones (Fig. 7). Combined with the fact that HRV14 is
unable to kill all I421-transduced HeLa cells during an
infection, the results suggest that I421 may act to block the
virus at an early step in its life cycle.
The level of ICAM1, the cell surface receptor for
HRV14, is not altered in cells expressing I421 whether as
the pool of transductants or as the cellular subclone I421dp3
(Fig. 9 and data not shown). This suggests that I421 does
not act by preventing ICAM1 expression, which correlates
with the observation that HRV2 is inhibited as strongly by
I421 as either HRV14 or HRV16 (Fig. 6). While HRV14
and HRV16 use the ICAM1 receptor for initial binding to
the host cell (Hofer et al., 1994; Staunton et al., 1989;
Tomassini et al., 1989), HRV2 is a member of the minor
group of human rhinoviruses, which use the LDL receptor
instead (Greve et al., 1989). Thus I421 appears to act in a
receptor-independent fashion. Further work will be neces-
sary to dissect which step between receptor binding and
assembly of a functional RNA replication complex is inhib-
ited.
At least two other, more general, mechanisms of virus
inhibition should also be considered. I421 may (i) activate
the heat shock response, a block particular to rhinovirus, or
(ii) activate the interferon response, a more general antiviral
mechanism (Goodbourn et al., 2000). We have examined
the possibility of heat shock and find no evidence for the
induction of HSP 70 in I421 cells over the normal levels in
HeLa cells (Fig. 8). We have not yet examined the inter-
feron response in I421 cells; however, we note that (a)
I421-transduced cells do not show any significant growth or
proliferation defects either immediately after transduction
or upon long-term, subconfluent passage (Fig. 10); (b) there
is no evidence that they undergo apoptosis upon infection
by rhinovirus; and (c) they do not appear to confer an
antiviral state upon cocultured cells (data not shown); i.e.,
the perturbagen behaves in a cell autonomous fashion.
These observations seem inconsistent with the possibility of
a strong interferon induction by I421.
I421dp clones
Random clonal lines of I421-transduced cells exhibited
several phenotypes. Four of nine lines of HeLa cells stably
transduced with I421 did not support plaque formation. In
contrast, all of the 10 stable lines of HeLa cells bearing
control vector examined were permissive for HRV14 plaque
formation. These data support several inferences. Impor-
tantly, I421 coding sequences are necessary for the HRV-
resistance phenotype of these HeLa cells. Furthermore, the
frequencies of I421dp lines exhibiting HRV14 plaque inhi-
bition and delayed/reduced viral replication suggest that the
observed viral resistance embodied in these clones is not the
product of mutations in cellular genes which act either alone
or in conjunction with the perturbagen to block HRV-14
growth. It is possible, however, that a common genetic
variant in the parental HeLa population acts in concert with
I421 to confer elevated levels of viral resistance. The fact
that 3 of 9 clonal lines of I421-transduced cells became
inviable during the course of high-density growth in the
plaque assay is intriguing and warrants further investiga-
tion.
Future work
The inability-to-plaque phenotype of I421dp cells opens
the way to isolating mutant virus that are resistant to the
action of the I421 perturbagen. Sequence analysis, and re-
construction, of such a mutant can often provide valuable
information about the mechanism by which the virus over-
comes the inhibitory block and therefore about the inhibi-
tory condition itself (Baginski et al., 2000; Heinz and
Vance, 1995; Mosser et al., 1994; Sherry and Rueckert,
1985).
The fundamental strength of the transdominant approach
that we have applied to find antiviral perturbagens lies in the
genetics. First, libraries of high complexity can be screened
en masse in these cell culture assays. Complementary DNA
libraries permit identification of proteins, protein fragments,
or peptides that possess classical hypermorphic or dominant
negative activity. On the other hand, it is relatively simple to
generate synthetic peptide libraries of 107–109 complexity
from random oligonucleotides. Random peptide libraries
have the added advantage of being normalized. Second,
molecular tools are readily available to retrieve and manip-
ulate perturbagens of interest. Third, the perturbagen (in this
case, the I421 peptide) can serve as a probe to identify its
cellular target, if it is a protein, by conventional interaction
technologies like the yeast two-hybrid assay or biochemical
affinity methods combined with mass spectrometry or pep-
tide sequence analyses. Fourth, the bioassay described here
has a large dynamic range so it should be possible to
mutagenize the coding sequence of I421 to select for vari-
ants conferring increased resistance to the virus. Structure–
activity relationships (SAR) with I421 can confirm the va-
lidity of a target and shed light on its mechanism of action.
Once armed with a protein target, one may proceed to
identify small molecules that can displace a fluorescently
labeled perturbagen from the target (discussed in Kamb and
Teng, 2000) and eventually determine if any of those small
molecules can confer HRV resistance. Alternatively, one
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may apply peptidomimetic approaches to I421 to directly
develop a therapeutic agent.
Materials and methods
Growing cells and virus
H1-HeLa cells (ATCC CRL-1958) were propagated as
monolayers in DMEM media (Invitrogen) supplemented
with 10% FBS, 2 mM L-glutamine, 1 MEM nonessential
amino acids, 1 mM Na pyruvate (DMEM10%). Cultures
were grown at 33°C in humidified chambers with 5% CO2
unless otherwise indicated. When necessary, clones of cell
lines were isolated using a Coulter Epics Elite FACS to sort
single cells into a 96-well microplate. Human rhinovirus
serotypes 2, 14, and 16 and Coxsackievirus B3 (HRV2,
HRV14, HRV16, and Cox B3) were obtained from the
American Tissue Culture Collection (ATCC VR-482, VR-
284, VR-283, and VR-30, respectively). To obtain virus
stocks, subconfluent cultures of HeLa cells were infected
with HRV14 virus in DMEM containing 2% serum
(DMEM2%) and harvested after 95% cell death was
observed (3–7 days). Cells and media were collected,
frozen and thawed three times at 80°C, and centrifuged at
1200g to remove debris. Virus preparations were stored at
80°C in aliquots. Viral stocks were titered by determining
the TCID50 (Reed and Muench, 1938) or by plaque assay.
Neutralizing HRV14 monoclonal antibody
The hybridoma cell line producing mAb17 (a gift of Tom
Smith, Purdue University, West Lafayette, IN) was the
source of a HRV14 neutralizing monoclonal antibody
(Sherry et al., 1986). Cells were grown in an Integra Bio-
sciences Cell Line CL-350 Passive Membrane Bioreactor
according to the manufacturer’s instructions in DMEM me-
dia containing 10% FCS, 20 mM HEPES, and 45 nM
-mercaptoethanol at 37°C. Every 3 to 4 days, 5 ml of the
media was collected, centrifuged at 1200 g, and buffered
with 25 mM HEPES, pH 7.5. Pooled mAb17 preparations
were then titered for neutralizing activity and frozen at
80°C in aliquots. Neutralizing titer was determined using
a visual readout of virus cytotoxicity in a 96-well micro-
plate. A rhinovirus inhibitory unit (RIU) was defined as the
minimal amount of antibody necessary to inhibit cytotoxic-
ity to 1  104 HeLa cells caused by 2  105 TCID50 virus
(from a single reference stock of titer 6.3 106 TCID50/ml)
at 24 h of infection. After determining the inhibitory titer of
one particular reference stock of mAb, other preparations
were titered by comparison to this material. Before using the
mAb in different experiments it was titered in that assay to
determine the plateau region of the survivor versus mAb
dose curve.
Detection of dGFP, HSP 70, and ICAM-1
Western blots were performed following standard tech-
niques (Ausubel et al., 2001). Protein from 10,000 cell
equivalents was separated by SDS–PAGE (Novex) and
transferred to PVDF membranes (Millipore) using a Novex
apparatus. To detect GFP a rabbit polyclonal antibody
(Clontech, No. 8363-2) was used at a 1/1000 dilution and
the secondary antibody was a HRP-coupled goat anti-rabbit
IgG (Boehringer Mannheim, No. 1814141) used at a 1/5000
dilution. To detect HSP 70 the primary antibody was a
mouse monoclonal antibody (Santa Cruz Biotechnology,
SC-24, 1/500 dilution) and the secondary antibody was a
HRP-coupled goat anti-mouse antibody (SC-2005, Santa
Cruz, 1/1000 dilution). Bands were visualized with the
Amersham ECL detection kit.
Flow cytometry to quantitate cell-surface ICAM-1 (CD54)
was performed using R-phycoerythrin-conjugated mouse
monoclonal anti-CD54 antibody (BD PharMingen No.
555511) with a mouse monoclonal IgG1  (BD Phar-
Mingen No. 555749) as the isotype control. Cells were
trypsinized, washed once with PBS, and resuspended at 2
million per ml in PBS10% goat serum. Five microliters of
control or anti-CD54 Ab was added to 100 l of cells and
incubated for 30 min on ice with occasional mixing. The cells
were washed with a 10-fold excess of PBS and resuspended in
400 l of PBS containing 2% formaldehyde. Fluorescence
(448-nm argon laser excitation and 575-nm (FL2) emission)
was recorded using a Coulter EPICS XL-MCL flow cytometer.
Northern analysis of viral plus-strand RNA synthesis
Total RNA was isolated from infected cells using the
RNeasy Mini Kit (Qiagen). Purified RNA was quantitated by
OD260 and equal amounts were fractionated on a 1.0% form-
aldehyde–agarose gel. The gel was stained with ethidium bro-
mide to judge the integrity of the 16S and 28S ribosomal
RNAs and confirm equivalent loading of different samples.
The gel was then blotted onto Hybond XL membranes (Am-
ersham-Pharmacia-Biotech), baked at 80°C for 2 h, and incu-
bated for 1 h in hybridization buffer (7% SDS, 1 mM EDTA
in 0.5 M Na2PO4, pH 7.2) (Church and Gilbert, 1984). A
single-stranded radioactive DNA probe complementary to the
plus () strand of the HRV14 genome was prepared following
the protocol of Bednarczuk et al. (1991), using pWR3.26,
which contains a cDNA copy of HRV14 (a gift from Wei-
Ming Lee, UW Madison; (Lee et al., 1993)), as a template and
several primers complementary to the HRV14 plus strand.
Radioactive signals were detected and quantitated using a
Molecular Dynamics phosphoimager.
Preparation of a human placental cDNA retroviral
expression library
Details of the construction of the cDNA library expres-
sion library have been described (Richards et al., 2003).
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Briefly, poly(A) human placental RNA served as the tem-
plate for random primed first-strand cDNA synthesis using
a primer containing a specific Sfi site (GGCCATTATG-
GCC, “SfiA”) immediately adjacent to the random 9-mer. A
second primer containing a distinct Sfi site (GGCCAG-
GCGGCC, “SfiB”) adjacent to a 3 random 6-mer was used
to PCR amplify the cDNA. This was cloned into cognate Sfi
sites in the plasmid pVT352.1 which is a pCLBabe/LNCX
retroviral vector (a gift of I. Verma, Salk Institute, La Jolla,
CA) derived from pLNCX (Miller and Rosman, 1989). The
retrovirus produced from pVT352.1 contains a CMV pro-
moter driving the expression of a nonfluorescent variant of
GFP (specifically the mutation Y66F referred to here as
dGFP (Poritz et al., 2001)). The SfiB site is located at the 3
end of the dGFP coding sequence (Fig. 4). The library
complexity was approximately 12  106 clones.
Packaging and transduction of retroviral cDNA libraries
and clones
The retroviral infection step is referred to here as a
transduction to distinguish it from the subsequent infection
with rhinovirus. To generate retrovirus which can transduce
the cDNA into HeLa cells the retroviral vector DNA (15
g) was cotransfected with a plasmid expressing the
VSV-G envelope protein (10 g of pCMV-VSV.G) into 3
 106 293gp packaging cells (a gift of I. Verma, Salk
Institute) per T175 flask using LIPOFECTAMINE (Invitrogen)
following the manufacturer’s instructions. After 72 h at
37°C the retroviral supernatant was collected, filtered, and
frozen at 80°C. Transduction of the cDNA library or
sublibraries derived from the different rounds of selection
followed standard procedures (Burns et al., 1993). In brief,
2  106 H1-HeLa cells (grown at either 33 or 37°C) were
mixed with the retroviral supernatant and plated in a T175
flask at 33°C. In different experiments the ratio of the
volume of viral supernatant to total tissue culture media (20
ml DMEM10% containing 6 g/ml polybrene) varied up
to 50% vol/vol. After a 24-h incubation, the cells were
washed and cultured with fresh media for 2 to 4 more days
to allow expression of the genes carried on the transduced
retroviral construct. To determine the percentage of cells
transduced by a retroviral supernatant (and thus the titer and
m.o.i. of the transduction), fixed and permeabilized cells
were stained with antibodies recognizing the nonfluorescent
GFP scaffold and analyzed by flow cytometry. Over the
course of the selection, the titer of the retrovirus stock
varied between 3  105 and 5  106 transducing parti-
cles/ml and the percentage of transduced cells varied be-
tween 70 and 99%. From transductions done in parallel at a
1–5% retroviral supernatant the calculated m.o.i. of most
large-scale transductions fell between 1 and 4 virus trans-
ducing particles per cell (data not shown). In some cases
neomycin (500 g/ml Geneticin, Invitrogen) was used to
select for the stable integrants; cells were used in virus
resistance assays after 10 days of selection and the cells
were grown for up to 20 passages before a new stock was
thawed for use.
HRV14 survival assay for cycling and measuring virus
resistance
HeLa cells, either freshly transduced or after neomycin
selection, were grow at 33°C for at least 1 day before
infection. Five million cells were plated per T175 flask and
simultaneously infected with HRV14 at an m.o.i. of 10 in 20
ml of DMEM2%. In pilot experiments this m.o.i. killed 99
to 99.9% of the control cells in the standard assay. Several
procedures were used to minimize secondary infection of
the cells by progeny virus of the primary infection. Four
hours postinfection, 500 RIU of mAb17 (100 l) was added
to the media to inactivate virus released from cells. Twenty-
four hours after HRV14 infection the flasks were washed
with PBS to remove the floating and loosely adherent dead
cells, and DMEM10% containing mAb17 (one-tenth of
the original quantity) was added and the cultures were
shifted to 39°C. At 48 h postinfection cells were washed
with PBS, trypsinized, and counted either by hemacytome-
ter or by scanning the cells for 1 min on a Coulter Epics
flow cytometer running at high flow rate. To determine the
percentage survivors in the assay, cells containing the same
retroviral construct (plated at one-quarter to one-half the
density of the infected sample) were mock infected and then
treated identically. Some assays of individual retroviral
clones were performed in six-well Falcon Multiwell plates
with volumes scaled accordingly.
Preparation of sublibraries after HRV infection
To generate a perturbagen sublibrary, cells adhering at
the end of 48 h of exposure to HRV were trypsinized and
used to prepare genomic DNA (Trizol reagent, Invitrogen).
The integrated retroviral inserts were then recovered by two
stages of PCR amplification using oligonucleotides with
homology to sequences flanking the cDNA insertion site
(oVT181: 5-GGATCACTCTCGGCATGGACGAG and
oVT178: 5-ATTTTATCGATGTTAGCTTGGCCATT).
Specifically, genomic DNA from 10,000 to 700,000 cells
was added to a 100-l PCR containing 2.5 mM MgSO4, 1.0
M primers, 0.2 mM dNTPs, 100 g/ml BSA, and 10 units
HiFi Taq DNA polymerase (Invitrogen) in 1  buffer sup-
plied by the manufacturer. The mixture was denatured at
94°C for 5 min and then subjected to 20 cycles of 94°C for
15 s; 68°C for 140 s; followed by 68°C for 5 min. Ten
microliters of this primary reaction was used to seed a
secondary 200-l PCR mix and subjected to a cycle titration
under the same conditions (being sampled every 2 cycles
from 10 to 20 cycles). The cycle number that first produces
visible product on an ethidium bromide stained agarose gel
was used in a new 200-l reaction under the same condi-
tions. PCR products were purified by phenol/chloroform
extraction and ethanol precipitation before being digested
181M.A. Poritz et al. / Virology 313 (2003) 170–183
with SfiI (New England Biolabs), purified through a
Chroma Spin 200 column (Clontech), and directionally li-
gated (T4 ligase, Boehinger Mannheim) into pVT352.1 vec-
tor that had been cut with SfiI and purified by agarose gel
electrophoresis. This DNA was electroporated into DH10B
(Electromax, Invitrogen) and selected on LB-Amp plates.
Colonies were scraped from the plate and plasmid DNA was
purified using a Qiagen kit. To maximize the chance of
recovering rare clones we scaled the ligation and transfor-
mation to generate at least 10-fold more E. coli colonies
than the number of HeLa cells recovered from the selection.
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